[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.216.242. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Correspondence
May 2000

Treatment of Severe Psoriasis With Anti-CD25 Monoclonal Antibodies

Arch Dermatol. 2000;136(5):675-676. doi:

Specific targeting of activated T cells to treat severe psoriasis vulgaris and generalized pustular psoriasis was first done by using intravenous anti-CD4 monoclonal antibodies.1,2 Improvement occurred; however, a rapid flare was also noted. Recently, systemic treatment with an interleukin 2–diphtheria fusion toxin (DAB389IL-2) was shown to be effective in about 40% of patients with severe psoriasis.3

First Page Preview View Large
First page PDF preview
First page PDF preview
×